We have developed efficient and accurate gene editing tools that can be applied to the treatment of genetic diseases and other fields.
Our Services
Develop high-performance biomaterials for tissue engineering, drug delivery, and other fields.
The developed biodegradable biomaterials have been applied in the medical field.
About us
BioNova Dynamics is an innovative company dedicated to driving breakthroughs at the forefront of biotechnology. Focusing on gene editing, cell dynamics and biomaterials, we develop revolutionary therapeutics and high-performance biomaterials through our self-developed core technology platform, bringing new hope to human health. Our mission is to become a global leader in biotechnology and drive the future of health.
With our mission to "Innovate the Future of Health", we are committed to solving major challenges in the field of human health through cutting-edge technology.
We have established long-term cooperative relations with many enterprises to jointly carry out cutting-edge technology research.
Marketing strategy
Precision medicine
We focus on providing personalized treatment plans tailored to the patient's genetic makeup and disease characteristics. Covering various diseases, genetic disorders, and rare diseases, our goal is to combine precise diagnosis and treatment to improve outcomes and enhance patients' quality of life.
Regenerative medicine
We develop advanced biomaterials and technologies for tissue repair and organ regeneration. By applying innovative techniques to repair damaged tissues and restore function, we are driving the clinical application of regenerative medicine to improve patient health and quality of life.
Biopharmaceuticals
We offer gene editing and cell therapy services to pharmaceutical companies, accelerating the new drug development process. By utilizing advanced technologies, we reduce clinical trial timelines, improve drug development efficiency, and drive the rapid market launch of innovative drugs.
BioNova DynamicsIgniting the Next Wave of Bio-Innovation
Driving Dynamic Solutions for a Healthier Future.
Our advantages
Based on CRISPR-Cas9 technology, efficient and precise gene editing tools have been developed to achieve knockout, insertion, and modification of specific genes. The gene delivery system with independent intellectual property rights can efficiently and safely deliver gene editing tools to target cells. A complete detection system for off-target effects of gene editing has been established to ensure the safety and effectiveness of gene editing.
In-depth study of the function and regulatory mechanism of immune cells, and development of new immune cell therapies. Advanced cell culture and expansion technology enables large-scale production of high-quality immune cells. A complete cell therapy safety evaluation system has been established to ensure the safety and efficacy of cell therapy.
Development of biomaterials with good biocompatibility, degradability and mechanical properties. With advanced material preparation and processing technology, biomaterials of various shapes and structures can be prepared. A complete safety evaluation system for biomaterials has been established to ensure the safety and effectiveness of biomaterials.
15
%
IDO
10
%
Tech
10
%
Operation
15
%
Foundation
50
%
Mining
Token
Token Name：BND
Initial Issuance：300 million
Our Team
She graduated from the Massachusetts Institute of Technology (MIT) with a Ph.D. in molecular biology and bioengineering,She has worked in a research team at one of the pioneers of CRISPR technology and was involved in the development of a new generation of CRISPR-Cas9 systems.
Jane Smith
He has an interdisciplinary background in computer science and genomics, and has worked for one of the top biotech companies in Silicon Valley Several software tools have been developed for CRISPR experimental design and data analysis.
James Wilson
She has a double degree in bioethics and law and has worked for the United Nations Educational, Scientific and Cultural Organization (UNESCO) Research focuses on the ethical, legal, and social implications of gene editing technologies.
Ann Williams
Our Partners
